Aurobindo Pharma Limited reported unaudited consolidated earnings results for the third quarter and nine months ended December 31, 2017. For the third quarter, revenue from operations was INR 43,361 million compared to INR 39,062 million a year ago. EBIDTA (before Forex & other income) was INR 10,256 million compared to INR 8,948 million a year ago. PAT (after JV share, minority interest) was INR 5,950 million compared to INR 5,786 million a year ago. Basic and diluted EPS was INR 10.16 compared to INR 9.88 a year ago. Profit before tax was INR 9,018.0 million against INR 7,961.7 million a year ago. Revenue increased by 11% year-on-year, driven by strong growth in the U.S., Europe and Growth Markets. Net profit increased by 2.8% year-on-year. As for the newly enacted tax reform act, the deferred tax assets and liabilities of the U.S. entity have been re-measured, resulting in a onetime charge of INR 664 million. The company generated cash flow to the tune of around $93 million. Net capex for the quarter is around $27 million.

For the nine month, revenue from operations was INR 124,507 million compared to INR 114,482 million a year ago. EBIDTA (before Forex & other income) was INR 29,845 million compared to INR 27,130 million a year ago. PAT (after JV share, minority interest) was INR 25,875 million compared to INR 17,692 million a year ago. Basic and diluted EPS was INR 32.34 compared to INR 30.23 a year ago. Profit before tax was INR 25,874.7 million against INR 24,081.3 million a year ago. Net debt was INR 34,495 million.

For the fiscal year 2018, the company expects that company will end up the year with tax rate of 26.5%.

For the fiscal year 2019, the company expects tax rate of 24.5% to 25.5%.